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Abstract
Background: With the explosion in data generated using microarray technology by different
investigators working on similar experiments, it is of interest to combine results across multiple
studies.
Results: In this article, we describe a general probabilistic framework for combining high-
throughput genomic data from several related microarray experiments using mixture models. A
key feature of the model is the use of latent variables that represent quantities that can be
combined across diverse platforms. We consider two methods for estimation of an index termed
the probability of expression (POE). The first, reported in previous work by the authors, involves
Markov Chain Monte Carlo (MCMC) techniques. The second method is a faster algorithm based
on the expectation-maximization (EM) algorithm. The methods are illustrated with application to
a meta-analysis of datasets for metastatic cancer.
Conclusion: The statistical methods described in the paper are available as an R package,
metaArray 1.8.1, which is at Bioconductor, whose URL is http://www.bioconductor.org/.
Background
With the increasing availability of published microarray
data sets, there is a tremendous need for developing
approaches to validate and integrate results across multi-
ple studies. One major issue to deal with in the meta-anal-
ysis of DNA microarrays is the lack of a single standard
experimental platform for data generation. The dominant
technologies so far have been two-color microarrays and
oligonucleotide (e.g., Affymetrix GeneChip) arrays.
Because these technologies measure fundamentally differ-
ing genetic materials designed to represent identical tar-
gets, many properties of expression measurements may
vary across platforms including scale of measurements,
sensitivity in detecting fold changes, control of cross-
hybridization, and so forth. The heterogeneity in array
design poses a great challenge for cross-platform compar-
isons and integration of results across independent micro-
array studies. The general area of combining data across
multiple studies is referred to as meta-analysis [1,2].
Many approaches have been proposed for meta-analysis
of microarray data. Rhodes et al. [3] combined evidence of
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the p-values from comparing cancer versus normal sam-
ples across multiple gene profiling studies and adjusted
for multiple testing using q-values [4]. Choi et al. [5] pro-
posed a Bayesian model for the effect size for genes from
multiple microarray experiments. In a more recent study
[6], data from one study were used to generate a prior dis-
tribution of the differences in logarithm of gene expres-
sion between diseased and normal groups, whose
distribution was then updated using other microarray
studies. These methods all model the effect size [1], or a
transformation thereof, across multiple studies.
Recently, we proposed a Bayesian mixture model-based
transformation of DNA microarray data based on a pro-
posal of Parmigiani et al. [7] and applied it to develop a
signature of breast cancer recurrence across multiple
microarray experiments from different platforms [8]. The
scale which was combined across studies is termed prob-
ability of expression (POE). The focus of Shen et al. [8]
was on the breast cancer application; here, we wish to
examine the technical aspects of the modelling used there.
Based on the probabilistic model that underlies the POE
methodology, one can exploit the notion of using latent
variables for combining genomic data from multiple
genomic studies. This is a very important idea that can
have more general applications than that considered by
Parmigiani et al. [7]. In Methods, we describe the data
structure and define two general probabilistic models for
quantities that are combinable across studies. The first is
the model used in [8]; we present it here for completeness.
The second is a two-component mixture model that can
be fit using an expectation-maximization algorithm. We
also relate the latent variables to recent statistical method-
ologies for differential expression as well as false discovery
rate [4,9]. We then illustrate the proposed methods with
an application to a meta-analysis of data comparing met-
astatic to localized cancer across multiple microarray stud-
ies in the Results section.
Results
Metastatic Cancer Study
We now discuss the application of the proposed method-
ology to a study looking at metastatic cancer. Based on the
availability of expression data for metastatic samples and
clinical information regarding the distinction of primary
and metastatic tumors, we selected three studies from
publicly available data sources [10-12]. These three stud-
ies were selected based on two criteria: 1) both localized
and metastatic samples are profiled, and 2) a reasonable
number of common genes appear across datasets. It
should be noted that generally only a small number of
metastatic samples are profiled, which was the case in all
three datasets. Throughout the article, the terms primary
and localized will be used interchangeably.
The goal of this meta-analysis is to identify the set of genes
that best distinguishes metastatic tumors from primary
tumors in human cancer tissue samples across distinct
organ sites. The method mentioned in the previous sec-
tion is applied to the three training sets to transform the
data to POE using both the EM and MCMC algorithms,
and an optimal signature based on leave-one-out cross-
validation logistic regression framework is obtained. The
method will be compared to a few alternative meta-ana-
lytic approach ([5,13]) in terms of the selected gene signa-
tures and the clustering of primary and metastatic tumors
based on them. Although the validation of methodology
is challenging, we used our gene signature to predict
metastasis-free survival time in the breast cancer study
proposed by van't Veer et al. [14] as a possible validation.
The hypothesis presumed here is that the profile for dis-
tinguishing metastatic from nonmetastatic tumors can be
used to predict aggressive cancer prognosis.
Data Description
Chen et al. [12] mainly focus on characterizing the global
gene expression patterns that distinguishes hepatocellular
carcinoma (HCC) from non-HCC samples using cDNA
microarrays. Our sample size numbers (see Table 1) are
different from theirs because we have excluded non-
tumor samples as well as repeat samples on the same
patient. Removing these samples leaves us with 69 unique
primary tumors and 9 liver tumors which have metasta-
sized.
Garber et al. [11] describe the diversity of gene expression
patterns in squamous cell carcinomas (SCC), large cell
lung carcinomas (LCLC), small cell lung carcinomas
(SCLC), and adenocarcinoma (AC) using cDNA microar-
rays. These four subtypes of lung cancer are often detected
in epithelial cells that line different sections of airways in
the lung, and their treatment options differ by these types
due to the pathological distinction among them. We first
Table 1: Description of data used in meta-analysis
Data Source Array Type Organ Site Sample # Metastatic # Primary
Chen et al. cDNA Liver 75 9 69
Garber et al. cDNA Lung 33 6 27
Latulippe et al. Affy U95 Human Prostate 32 9 23Page 2 of 20
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paired samples profiled at primary stage. Identifying and
removing duplicate samples was performed the same way
as for the Chen et al. data. The subset of patients included
in our meta-analysis were 27 primary adenocarcinoma
samples and 6 samples with lymph node metastases.
Finally, the Latulippe et al. [10] study identifies genes that
differentiates primary and metastatic cancers in the pros-
tate. Using Affymetrix oligonucleotide array U95 human
gene arrays, they reported gene expression profiles of
nearly 25,000 genes/ESTs. All samples were included in
our meta-analysis. The details for the three studies are
summarized in Table 1.
An important aspect of this collection of data is that the
organ sites are different. We are postulating a hypothesis
that there is a common profile separating localized
tumors from metastatic tumors across the three sites. Sim-
ilar evidence for this type of hypothesis has been sug-
gested before [15]. The microarray platform differs by
studies, so we mapped clone/probeset IDs to Unigene
cluster IDs (UGIDs) of its most recent build through
SOURCE [16]. UGIDs are constantly updated. Because
our initial mapping was done in the year 2004, we trans-
lated these UGIDs to the June 2006 build (No. 191) in the
NCBI database. The genes we report here and their anno-
tation in the remainder of the paper is consistent with all
annotations associated with the most up-to-date Unigene
clusters. When multiple clones are mapped to the same
UGID, we averaged the expression over the clones within
each sample. Such a mapping produced 1633 common
UGIDs.
POE
Before combining 140 samples from different sources
into a single dataset, we transformed the raw data to POE
from each study by normalizing the distribution of
expression values in metastatic samples to that of local-
ized samples. Note that the localized or primary tumors
represent the baseline group, since our goal is to select
gene signature that distinguishes metastatic tumors from
localized tumors, for which many conflicting hypotheses
have been postulated. The output of POE from each study
was then combined to form a single expression dataset
with 1633 genes and 140 samples.
In the following, the POE data transformations by the EM
and MCMC algorithms will be analyzed in parallel for the
sake of comparison. All primary tumors are color-coded
in red and metastatic tumors in green. In terms of compu-
tational speed, estimation of POE based on the EM algo-
rithm takes less than a minute for 1633 genes per dataset,
while that using MCMC takes about 50 minutes for 2000
iterations and 4 periodic skips in the sampler. As the num-
bers of genes and samples grow, this difference will be
substantial. For example, it usually takes 4 hours to fit
POE for a dataset with 10,000 genes using full Bayesian
modelling as opposed to 3 minutes for the maximum like-
lihood approach using the EM algorithm. The reason for
the computational difference is that the EM algorithm is
fit to one gene at a time, while the MCMC algorithm
involves fitting to expression measurements for all genes
simultaneously.
Figures 1 and 2 show the POE transformation for two
genes using both the EM and MCMC algorithms. In both
plots, the top panel shows the expression levels on the raw
scale, followed by those on the POE scale from the EM
and MCMC algorithms, respectively. The gene in Figure 1
is TGFB1 (UGID Hs.155218), which controls prolifera-
tion and differentiation in many cell types. The gene in
Expression of TGFB1Figure 1
Expression of TGFB1. Transforming growth factor beta 1 
(TGFB1) gene expression on raw (upper), POE EM (middle) 
and POE MCMC (lower) scales. This gene is uniformly 
underexpressed in metastatic samples. Open circles indicate 
primary tumor samples, and stars indicate metastatic sam-
ples.
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whose mutation leads to various forms of thrombosis and
which is often expressed in liver tissues.
Although both genes are in the signature obtained by our
methods, they clearly represent different types of genes.
Based on Figure 1, F2 is under-expressed in the metastatic
liver samples of Chen et al., weakly under expressed in the
lung samples of Garber et al., and not differentially
expressed in the Latulippe et al. data. It was found signifi-
cant only in the liver study among the three studies we
considered here. On the other hand, TGFB1 is a gene
whose expression is uniformly under expressed in meta-
static samples across all three studies.
This observation on the two types of expression pattern
on POE scale suggests that our signature will contain both
types of genes. As will be shown later, a conventional
meta-analytic approach that combines strength of differ-
ential expression across studies on the raw scale tends to
select genes that behave similarly to TGFB1, whereas our
method picks up both types of genes. Unless genes with
expression patterns similar to F2 dominate the entire sig-
nature, the gene set from our method tends not to be
influenced by a single study.
Signature Selection
As we proposed POE transformations using two different
implementations, we will refer to the signatures from the
data transformed by the EM and MCMC algorithms as the
POE EM signature and the POE MCMC signature, respec-
tively.
To obtain a gene signature that distinguishes metastatic
samples from localized samples, we calculated risk indices
for all samples. What we call a risk index is described in
the Methods section. A logistic regression is fitted for each
gene with one sample held out at a time. The response var-
iable is metastasis status (1 = metastatic, 0 = localized).
For all genes we iterated the same procedure holding each
sample out while recording coefficients β and p-values.
Following the risk index approach for classification
expalined in Methods section, we calculated risk indices
for all 140 subjects at various sizes of the gene signature.
The optimal signature size p was then determined based
on classification performance.
For classification purposes, we predicted the subjects with
positive risk index to be metastatic and those with nega-
tive risk index to be localized cancer. Using Figure 3, we
took the optimal size to be 80 for the POE EM signature
as the error rates in metastatic and primary tumor samples
collectively reach a minimum and do not decrease further
as more genes are added beyond 80. A similar criterion
was applied to obtain a 70-gene POE MCMC signature. A
plot of the risk indices and the optimal cutpoint is given
in Figure 4. The POE EM and POE MCMC signatures share
52 common UGIDs.
Comparison and Validation
We performed other analyses for the sake of comparison.
First, we compared the classification performance of the
signatures found using meta-analyses with that in which
the classifiers were constructed on one dataset only and
tested on the other two datasets. The performance is sum-
marized in Table 2. While such individual study-specific
signatures tended to perform well on the training dataset,
their performance did not generalize well to other data-
sets. The consistently poor performance of all signatures
on the Garber dataset, including its own signature, sug-
Expression of F2Figure 2
Expression of F2. F2 coagulation factor II (F2) gene expres-
sion on raw (upper), POE EM (middle) and POE MCMC 
(lower) scales. This gene is underexpressed primarily in met-
astatic samples of the Chen liver study. Open circles indicate 
primary tumor samples, and stars indicate metastatic sam-
ples.
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the others within the common subset of 1633 genes used
in this analysis.
We also compared our methods with two meta-analysis
techniques developed in [5] and [13]. The former per-
forms Bayesian inference on the classical Hedges-Olkin
pooled effect sizes for each gene from multiple studies,
and the latter uses Bayesian hierarchical model to pool
datasets across studies through group-specific mean and
variance parameterization and selects gene signature
based on their Bayesian estimate of FDR.
First, since the method of [5] pools the differential expres-
sion statistics from a collection of raw-scale data, there is
no analogue of a risk index-based classification method
available using their signatures. Instead, we first obtained
a signature of size 80 based on univariate gene selection.
Here the choice of size 80 in all signatures was chosen to
provide a fair comparison of class prediction power with
POE signatures. This corresponds to controlling the FDR
at 0.02 in the method by [5]. We call this the effect size
(ES) signature. We also fitted the hierarchical model from
[13] using WinBUGS software [17]. We used the prior
specification reflecting vague prior information as in the
original paper. The fitted model was obtained from a sim-
ulation of 12,000 iterations with the initial 2,000 itera-
tions used for burn-in. The estimated probabilities of
differential expression were surprisingly low, with the
highest probability 0.003. This implies that the 80 gene
signature has FDR 99%. For the sake of comparison, we
also took the 80 gene to assess its class prediction ability.
We call this Conlon signature. Since both POE and the lat-
ter method report the probability of differential expres-
sion of individual genes, we examined the concordance
between the two sets of probabilities. Figure 5 shows the
probability in Conlon et al. plotted against that in POE
EM. The ES signature shared 15 UGIDs in common with
the POE EM signature and 18 genes with the POE MCMC
signature only, which suggests that the two signatures will
have different characteristics.
Risk indexF gure 4
Risk index. Derived risk indices from the data transformed 
by the EM and MCMC algorithms. Primary and metastatic 
tumors are represented by open circles and stars respec-
tively. The y-axis is risk index.
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Misclassification Error. Misclassification error rates in 
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BMC Bioinformatics 2007, 8:364 http://www.biomedcentral.com/1471-2105/8/364Meanwhile, the Conlon signature had an overlap of two
genes with the ES signature and one gene with the POE
EM and MCMC signatures. The poor overlap of Conlon
signature with others is consistent with the high Bayesian
FDR estimated above.
To assess the classification performance, we performed
hierarchical clustering of tissue samples from the individ-
ual studies using the ES signature. Figures 6 through 8
show the heatmaps of the ES signature in individual stud-
ies with clustering tree. These were drawn separately
because the raw scale data cannot be directly combined as
in POE. Figures 9, 10 are the heatmaps of the POE EM and
MCMC signatures. To highlight the sample labels in each
plot, a yellow/blue color strip was added to the top of the
dendrograms through Figures 6, 7, 8, 9, 10, which should
be viewed along with the breakdown of the clustering tree.
For all plots, we used average linkage clustering with the
distance metric defined using the Euclidean metric. This
was also done for the Conlon signature [see Additional
Files 1, 2, 3]. We found that the clustering performance of
this signature was similar to that in the ES signature as
well, with most of the errors committed in Garber lung
study. The overall classification performance across all sig-
natures is provided in Table 2. Based on the classification
table, we see that the proposed methods (EM and MCMC)
greatly outperform the Conlon signature, while they also
are superior to the ES method, although this difference is
smaller.
We note that clustering with all signatures give fairly accu-
rate results in all three studies. In the ES signature, only a
few metastatic samples are grouped together with two
other primary tumors for the Chen liver study (Figure 6).
Two metastatic samples are situated under the same node
with primary tumors in Garber lung study (Figure 7),
Finally, one primary and another three metastatic samples
are in the opposite clusters in Latulippe prostate study
(Figure 8). Overall, the clustering can differentiate meta-
static tumors from primary tumors, although some meta-
static tumors were grouped with primary tumors. The
Conlon signature had no classification error in Latulippe
prostate study, but essentially there was no tight clustering
in Garber lung study at all, although 4 out of 6 metastatic
samples were clustered together in a local tree.
The POE EM and MCMC signatures give comparably good
clusterings of the two types of tumors across all studies. In
Figures 9 and 10, all metastatic tumors except for two
samples from the Garber lung study are grouped together,
and some primary tumors from the Chen liver study are
separated from other primary tumors. Furthermore, the
lengths of the edges to the leaf nodes in the dendrogram
are shorter than that in the ES signature, which suggests
that the clustering of primary tumors is tighter than that
using the ES signature. This is a consequence of normaliz-
ing the expression level of metastatic tumors to the distri-
bution of primary tumors by utilizing phenotypic
information in the estimation of POE. The heatmaps vis-
ually demonstrate the difference between the ES signa-
tures and the POE signatures. We next used NIH DAVID
[18] to determine if there were functional groups enriched
for in our gene expression signatures. In terms of gene
annotation, the POE EM and MCMC signatures share
many common functional categories because they have
many UGIDs in common such as response to stress,
immune response, endopeptidase and enzyme inhibitor
activity, cell organization and biogenesis, and regulation
of cell cycle. The class of functions common to the POE
and ES signatures is cell cycle processes. GO terms such as
antigen processing, endogenous antigen via MHC class I,
DNA repair, many metabolism and transport activities
appear in the ES signatures only. Also, a literature search
has suggested the association of POE signature genes and
their corresponding GO terms with tumor invasion and
metastasis in various cancer types. For example,
ALDH1A1 (stress response) and MAPK3 (cell prolifera-
tion) are targets of the HGF/MET signaling pathway which
has been associated with tumor metastasis and poor prog-
nosis in human hepatocellular carcinomas [19]. In
Table 2: Classification error rates
Chen Garber Latulippe
Chen (50) 0 27 21
Garber (25) 18 12 18
Latulippe (30) 17 21 0
POE EM (80) 2 6 0
POE MCMC (80) 1 6 0
Effect Size (80) 1 12 0
Conlon et al. (80) 7 27 0
Table entries are misclassification error rates in percentage points using classifier from study on row to predict that listed in the column. Number 
in parentheses in the signature column refers to number of genes at which classification accuracy was optimized. E3ect Size refers to method of [5].Page 6 of 20
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POE and Conlon et al comparisonFigure 5
POE and Conlon et al. comparison. Concordance of the gene specific probability of differential expression between the 
POE (EM) and the method in [13].
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Chen et al. dataFigur  6
Chen et al. data. Hierarchical clustering of tumors in Chen et al. data using the effect size signature. The expression here is 
on the raw scale. The color strip in blue and yellow below the heatmap indicates primary and metastatic tumors. Blue indicates 
primary tumors and Yellow indicates metastatic tumors.
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Garber et al. dataFigure 7
Garber et al. data. Hierarchical clustering of tumors in Garber et al. using the ES signature. The expression here is on the 
raw scale. The color strip in blue and yellow below the heatmap indicates primary and metastatic tumors, respectively
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Latulippe et al. dataFig re 8
Latulippe et al. data. Hierarchical clustering of tumors in Latulippe et al. using the ES signature. The expression here is on 
the raw scale. The color strip in blue and yellow below the heatmap indicate primary and metastatic tumors, respectively.
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POE EM for all three datasetsFigure 9
POE EM for all three datasets. Hierarchical clustering of tumors of all three studies using the POE EM signature. The 
expression is on the POE scale.
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POE MCMC for all three datasetsFigure 10
POE MCMC for all three datasets. Hierarchical clustering of tumors of all three studies using the POE MCMC signature. 
The expression is on the POE scale.
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BMC Bioinformatics 2007, 8:364 http://www.biomedcentral.com/1471-2105/8/364another example, overexpression of PFN2 (Regulation of
actin cytoskeleton) and UBS (stress response) has been
associated with lymph node metastasis of gastric cancer
[20] and colon cancer [21] respectively. These observa-
tions indicate that the POE signatures lead to relevant
findings toward understanding the potential mechanism
of differentiation of metastatic tumors from primary
tumors.
Finally, an additional validation of the method was
attempted to see if the resulting gene expression signature
can discriminate lethal from nonlethal cancers in an early
detected population of cancers. Note that the signature
selection was primarily oriented toward the distinction of
metastatic tumors from primary tumors. Thus validation
here is based on the conjecture that many metastatic
tumors are highly likely to initiate lethal condition. We
addressed this issue by using the data from the van't Veer
et al. [14] study. Their study profiled 98 primary breast
cancer samples in Hu25K inkjet arrays. Among these
patients, 34 patients developed distant metastases within
5 years, 44 patients continued to be disease-free after a
period of at least 5 years. Other 20 patients either had
BRCA1 germline mutations or were BRCA2 carriers; we
excluded these samples from the analysis.
The study was based on a large inkjet microarray profiling
over 25,000 probes. About two-thirds of 1633 genes used
in the three cancer studies appear in the Van't Veer et al.
data. Based on the classifier trained from the three cancer
datasets described above, we mapped the genes from the
signatures to those in the van't Veer et al. data. We gener-
ated risk indices for subjects in van't Veer et al. Specifically,
we first transformed the van't Veer et al. data to the POE
scale using both the EM and MCMC algorithms without
using the phenotypic information to prevent overfitting.
Note that we did not consider the effect size and Conlon
signatures here. Then we calculate the log odds ratio for
each patient using the coefficients trained from training
data and the newly generated POE data. Note that the esti-
mated regression coefficients for the risk score came from
the training set. As expected, the derived risk indices using
the data from the EM and MCMC algorithms are highly
correlated (Pearson correlation 0.83).
A proportional hazards model [22] relating metastasis-
free survival to the risk index, adjusting for covariates, was
fit to the data. Tables 3 and 4 shows the results. In both
analyses using data from the EM and MCMC algorithms
concur in that the derived risk indices are strong predictor
of metastasis-free survival times. This association remains
strong even after adjusting for estrogen receptor status and
age. Since we are interested in risk prediction, we calcu-
lated the C-index [23] to see if the gene expression signa-
ture adds discriminatory information relative to estrogen
status and age. For the model with just age and estrogen
status, the C-index is 0.714. For the EM-based POE signa-
ture, the C-index with all three variables (Multivariate
model in Table 3) is 0.722. For the MCMC-based POE sig-
nature, the C-index with all three variables (Multivariate
model in Table 4) is 0.748.
Discussion
Ideally, we wish to use all common genes from the avail-
able studies for meta-analysis. However, one issue that
has been debated recently is that of reproducibility of
genes across studies [24,25]. A technique that has proven
to be useful as a filtering device to enhance comparability
across arrays of different platform1s is the integrative cor-
relation coefficient or correlation of correlation coeffi-
cients [24,25]. The idea underlying this method is that
while raw expression values vary from study to study, the
intergene correlations do not vary as much. The intergene
correlations are calculated across all samples; this yields a
N × N matrix for each study. The row-wise averages are
taken for each study and then calculated, and the correla-
tions of these averages between these studies is then calcu-
lated. Thus, one would consider combining genes that
have similar intergene correlations across the studies. For
normally distributed data, the sample correlation is inde-
pendent of the sample mean. Thus, genes selected based
on an integrative correlation filter need not necessarily be
highly expressed genes. We could perform this as a filter-
ing step before applying the proposed meta-analysis
methodologies; we did not do so here. The drawback to
such a measure is that the filtering of genes might reduce
the chance of finding subtypes in the datasets because the
genes that define such subtypes may be excluded based on
the integrative correlation coefficient.
Table 3: Results of EM POE-based survival analysis
Analysis Variable Coef p-value
Univariate Risk Index 0.015 0.005
Multivariate Risk Index 0.010 0.049
Estrogen Receptor Pos -0.697 0.058
Age -0.059 0.021
Cox proportional hazards model fitted to time to distant metastasis in lymph node from study by [14]. Risk indices were derived based on POE 
data transformed by the EM algorithm.Page 13 of 20
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BMC Bioinformatics 2007, 8:364 http://www.biomedcentral.com/1471-2105/8/364One limitation of our methodology is that it is still subject
to the usual meta-analysis assumption that the trans-
formed expression measurements (the POE values) are
directly combinable across studies. If in fact we are trying
to combine measurements for fundamental different
quantities across multiple studies, then this in fact renders
the meta-analysis invalid. However, for that situation
most meta-analytical approaches are invalid, and one
would need more sophisticated modelling assumptions.
A related issue to this is that of heterogeneity. The results
of the analysis here should be interpreted with some cau-
tion in that we are comparing metastatic versus nonmeta-
static tumors across a variety of tissue types. We made the
assumption that the differences between the two types of
tumors are the same across the three studies. If this is not
true, then it might be quite possible that what we are
detecting are in fact tissue-specific differences between
metastatic and non-metastatic tissues. It is of interest to
develop methods for assessing heterogeneity in meta-
analyses of genomic data so that they may be applied
before using the proposed methodology in the paper.
Conclusion
With the proliferation of genomic datasets from related
studies by different scientific groups, an important
method for increasing power will be to combine results
across the different studies. In this article, we have pro-
posed a model-based approach to doing this. Being able
to integrate and interpret multiple genomic datasets will
be an important enterprise for data analysts working in
bioinformatics to address in the future.
A question orthogonal to that looked at in this paper but
of equal scientific importance is that of identifying genes
whose expression is correlated across a subset of the sam-
ples. This is referred to as molecular subtype analysis and
was in fact one motiviation of the POE algorithm pro-
posed by Parmigiani et al. (2002). However, finding such
gene signatures would require the use of completely dif-
ferent statistical methods than those proposed here and is
beyond the scope of the current paper.
Several important issues to consider when integrating
microarray studies include use of different gene expres-
sion measurement scales, varying analytical power and
reliability of the results for individual studies. To address
these issues in a meta-analysis framework, we proposed a
two-stage mixture modeling strategy. The goal of the mix-
ture model-based transformation is to transform the pre-
processed data to the probability scale, which are then
integrated across datasets. In particular, the signed proba-
bility of differential expression pd is easily interpretable
and is platform-independent. The Normal-Uniform mix-
ture distribution under a Bayesian hierarchical model set-
ting has several desirable properties. We have also
proposed an alternative model based on a two-compo-
nent mixture and estimation using the EM algorithm. We
briefly compare the MCMC and EM algorithms. The
advantage of the former method is that it pools informa-
tion across all genes, while the latger approach does not.
However, the EM algorithm is computationally much
faster than the MCMC scheme. In our example, we find
that there is substantial overlap between the two
approaches for the metastasis data considered here. How-
ever, we also expect that for cancer studies, the EM algo-
rithm would fare better with larger phenotypic differences
(e.g., non-cancer versus cancer tissue), while the MCMC
approach would be of use when the phenotypic differ-
ences in samples are subtle (e.g., Gleason score ≤ 7 versus
> 7 in prostate cancer).
Combining samples on the probability scale mitigates the
influence of potential artifacts from a single study. The
effect is reflected on two counts. One, integrated sample
cohorts improve the reliability of the findings by guarding
against false positive results from a single study. Two, it
increases the statistical power to detect small consistent
effects that can be otherwise masked by inadequacy of the
sample size of an individual data set. By implementing
this modeling approach, we were able to combine infor-
mation from three microarray studies to build an inter-
study validated signature for discriminating metastatic
cancer from non-metastatic cancer.
Table 4: Results of MCMC POE-based survival analysis
Analysis Variable Coef p-value
Univariate Risk Index 0.036 < 0.001
Multivariate Risk Index 0.027 0.008
Estrogen Receptor Pos -0.580 0.120
Age -0.056 0.030
Cox proportional hazards model fitted to time distant metastasis in lymph node from [14]. Risk indices were derived based on the POE data 
transformed by the MCMC algorithm.Page 14 of 20
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BMC Bioinformatics 2007, 8:364 http://www.biomedcentral.com/1471-2105/8/364The statistical methods described in the paper are availa-
ble as an R package, metaArray, which is available through
the Bioconductor project at [26].
Methods
Data Structures and Probabilistic Models
Let  denote the gene expression measurement for gene
i from sample. j in study k, transformed using the base two
logarithm, i = 1, ..., N, j = 1, ..., Mk, k = 1, ..., K. Note that
we assume that there are N common genes in all K studies,
but the number of arrays in studies may vary. We also
assume that preprocessing has been done, either by a low-
ess normalization for two-channel microarray data [27] or
a robust multichip average analysis for Affymetrix data
[28]. Then the available data can be denoted by ,
where Xk is a N × Mk matrix whose (i, j)th entry is . Note
that the value and interpretation of  is inherently dif-
ferent across array platforms and is not necessarily compa-
rable if they are measured from independent studies.
Corresponding to , let  be a variable that takes one
of three values {1, 0, -1}, indicating over-, baseline- or
under- expression respectively for gene i in sample j for
the study k. If  were known, then this is a gene-specific
quantity that would provide a platform-free scale which
could be combined across multiple studies. We approach
this problem by treating  as a latent variable that is
inferred from the data using a mixture model. We now
present two probabilistic specifications for making infer-
ence about . The first was presented in [8]; we describe
it here for the sake of completeness. The second assumes
, take two values of 0 and 1 and involves fitting a two-
component mixture model using the EM algorithm. Both
specifications aim to map the original expression values
to POE values within a study. We then can combine the
POE values across the multiple studies. In the simplest
case, a direct group comparison can be made by calculat-
ing t-statistics or applying significance analysis of microar-
rays [29] to the combined data. In the remainder of this
section, we describe the two approaches for obtaining
POE expression values. From here on, we suppress the
study indicator k throughout this section because estima-
tion is performed within each study separately, with the
only exception being the use of Mk to denote the number
of samples in study k.
Bayesian Model-based Approach and Algorithm
This approach was first explored for a single study setting
in [7] and used in the meta-analysis setting in [8]. We
present it here for the sake of completeness. The estima-
tion of the POE values involves borrowing information
across all genes.
First, the model specification is described. Following the
approach of [7], we assume that the expression xij of gene
i in sample j is a realization of the following mixture
model:
where µi is the gene-specific effect of gene i, αj is the sam-
ple-specific effect in sample j. For the purposes of identifi-
ability, sample effects  are constrained to sum to
zero. The parameters  and  provide limits to the
uniform distribution in the mixture of gene i, and are set
to be at least either 3σi away from the mean of normal dis-
tribution or farther away than the most outlying expres-
sion. The parameters  ≡ P(eij = 1) and  ≡ P(eij = -1)
are the multinomial probabilities for the latent variable
. Conceptually, we can think of gene expression for the
i-th gene arising from three types of genes in model (1).
The first component in the model represents the type of
genes whose expression levels are overexpressed in the
cancer samples relative to the normal samples. The second
corresponds to genes that do not change between cancer
and normal samples, and the third is for genes that are
underexpressed in cancer samples relative to normal.
Let  ≡ P(eij = 1|xij) and  ≡ P (eij = -1|xij) be the condi-
tional probabilities of over and underexpression for gene
i in sample j given the microarray measurements. By
Bayes' rule,
xij
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where f0i is the normal density function, and f1i, f-1i are the
corresponding uniform densities for the differential
expression categories for the gene i in each study. In the
numerator of (2), f1i = 1/  if xij ∈ [µi + αj, µi + αj + ]
and 0 otherwise. In the numerator of (3), f-1j = 1/  if xij
∈ [-  + µi + αj, µi + αj] and 0 otherwise.
Note that the supports of the two uniform distributions
are disjoint. As a result, the probabilities of differential
expression are mutually exclusive with the following
forms:
We then construct the following expression measurement:
, ranging from -1 to 1. This is the probability
of expression (POE); it can be interpreted as the signed
conditional probability of differential expression of gene i
in sample j in an individual study. On first glance, our for-
mula differs from that in [7] in that their POE measure,
corresponding to , involves addition, while ours
involves subtraction. The two are equivalent, however,
since their second probability is constrained to be nega-
tive, while  is constrained to be positive.
To sample from the posterior distributions of the param-
eters, a Gibbs sampling algorithm (with Metropolis-Hast-
ings step for mixture proportion parameters) was then
implemented where the gene-specific parameters were
repeatedly sampled from the corresponding full condi-
tional distributions [See Additional File 4]. We thus fit the
Bayesian algorithm to each microarray dataset separately.
Note that there is one normal component distribution to
the mixture, while the other two are uniform distribu-
tions. The reason we prefer this to a three-component nor-
mal mixture model is so that the probabilities of
expression are monotonic functions of absolute gene
expression. It can be shown that using a three-component
normal mixture model, the POE is no longer a monotonic
function of gene expression. It is desirable to have the
monotonicity property as we would like larger differences
in gene expression relative to a baseline group to be asso-
ciated with greater statistical evidence of differential
expression. Note that this is a standard assumption made
in the meta-analysis methodologies.
There are several advantages to the mixture model-based
transformation. First, the method estimates the posterior
distribution for the latent variables eij, which can then be
combined across multiple studies. Second, the trans-
formed values carry meaningful interpretations as signed
probabilities of differential expression of a gene in a par-
ticular sample. Third, the underlying normal and uniform
mixture distributions give equal density in the tails and is
effective in reducing the influence of extreme expression
values. Finally, the Bayesian hierarchical modeling
approach borrows strength across genes, resulting in
shrinkage-type estimators for the gene-specific parame-
ters. Consequently, the high-dimensional gene expression
data are denoised. However, the algorithm for inferring
the posterior distribution of the latent variables is fairly
computationally intensive. In the next section, we discuss
an alternative mixture model specification that leads to a
more computationally efficient algorithm.
Maximum Likelihood Approach using EM algorithm
Maximum likelihood estimation (MLE) using the EM
algorithm leads to greater increases in computational
speed for mixture models. Such an approach might be
useful since what we are interested in eventually is esti-
mates of POE that we can integrate across studies. There is
a difficulty in implementing an EM algorithm for the
three-component mixture model we considered in the
previous section. Recall the restriction that the uniform
components must have the same heights. Since the MLE
of end points of uniform distributions are the most outly-
ing observations, we have found in some examples that
the EM algorithm with these MLEs provides parameter
estimates that are unstable.
As an alternative modelling approach, suppose we take
the three values for the latent variables eij from the previ-
ous section (eij = {-1, 0, 1}) and collapse them into two
possible values, eij = 1 and eij = 0. Note that for the ith gene
and jth sample, eij = 1 corresponds to differential expres-
p
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ential expression. We now consider the following two-
component mixture model for the ith gene:
where µi is the mean of the normal distribution, πi is the
mixing proportion and ai, bi are the two end points of Uni-
form distribution respectively. Conceptually, there are
only two populations of genes in model (4). There is a
constitutively expressed population common to both
tumor and normal samples (the normal component) as
well as a differentially expressed part (the uniform com-
ponent). Such a model has been proposed in the situation
for K = 1 in [30]. Their interest was in determining differ-
entially expressed genes within one study, while ours is in
combining results across multiple studies.
For a fixed i (gene), the likelihood to be maximized for
each gene is the following:
It is simple to find parameters that maximize the mixture
model likelihood using the EM algorithm [31]. Maximiza-
tion is accomplished by iterating between the following
steps. In the E step, we calculate
where t indexes the iteration of the EM algorithm, and eij
is the unobserved indicator for the gene i in sample j to
have originated from the uniform component of the mix-
ture distribution. In the M step, we calculate
As mentioned in [30], ai and bi are estimated by the mini-
mum and maximum of the xij for a fixed j. We obtain esti-
mates of eij, , after the EM algorithm converges. To
construct estimates of POE, we take  and make it nega-
tive for those samples whose observed expression was to
the left of the mean of the baseline distribution of expres-
sion for each gene. This places the POE values from this
model on the same scale as those from the three-compo-
nent mixture model. In terms of initial values for the mix-
ture model and in particular eij, they were set at zero for all
points except those that were three standard deviations
from the mean expression.
Such an approach is much less computationally challeng-
ing compared to the Markov chain Monte Carlo described
in the previous section. In particular, the MCMC method
requires iterating over all N genes, while the EM algorithm
is calculated for one gene at a time. Letting S and I denote
the periodic skip in Gibbs sampler and the number of iter-
ation respectively, the computation speed is O(NSI) for
the MCMC algorithm, while it is O(N) for the EM algo-
rithm. We compare the performances of the two methods
on a real dataset in the Results section.
Until now the discussion of transforming data into POE
values has implicitly assumed that no phenotype informa-
tion was used in the estimation algorithm. Nonetheless,
there is often phenotypic data available in experiments,
which provides a priori information on the eij. In the exam-
ple considered here, the goal of meta-analysis is to com-
pare localized tumors from metastatic tumors. By using
phenotypic data, we are able to explicitly normalize the
POE values in metastatic tumors to those in localized
tumors. This involves making the likelihood a classifica-
tion likelihood in which we know the identities of the
samples. Letting  and  denote sets of sample labels
for the localized and metastatic tumor groups, respec-
tively, we can write the likelihood as
The derivation of the E- and M steps remains the same
except that at the M step,
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The resulting POE can be easily calculated using the sim-
ple estimate P( ) = | |/Mk, where Mk is the number
of samples in the kth study. We plug this estimate into the
calculation of POE for all genes and samples. However, at
the end of the iteration, we use Bayes' rule to get the pos-
terior probability of eij being one so that the POE values
are not zero.
To see what effects this procedure has, let us consider two
hypothetical situations. For the first situation, if the distri-
bution of expression in localized samples overlaps with
that of metastatic samples, then most POE values will be
near zero. This implies that not many samples will show
differential expression between the two groups. By con-
trast, if the expression values in metastatic samples are
concentrated in either tail relative to the distribution of
expression in localized samples, then resulting POE val-
ues will be larger in absolute value. POE values referenced
to one group may reveal the contrast between the two
groups, and will help denoise relative expression differ-
ences in the two groups when merging across independ-
ent datasets, which is otherwise potentially susceptible to
other grouping or study-specific effects. Such an adjust-
ment can also be easily incorporated in the full Bayesian
model. In our meta-analysis example, the basic principle
for both estimation procedures is to fix eij = 0 for localized
tumor samples across all genes throughout, and estimate
mixture proportion parameters π. With the π thus
obtained, we can estimate POE for both localized and
metastatic tumors. The Bayesian algorithm fixes eij = 0 for
the localized tumors during each iteration of the Gibbs
sampling algorithm.
Interpretation of Latent Variables
Note that the eij are the target quantities of interest within
each study. In particular, we note that much of the meta-
analysis literature for genomic data has focused on using
gene-specific summaries and combining them across
studies (e.g., [3,6]). We instead transform the raw data
directly; this may lead to potential gains in efficiency of
analysis.
While we describe potential meta-analytic approaches in
the next section, we mention two interpretations of the eij
themselves. First, we can define sample subtypes based on
the eij; this was also noted in [32]. Recently, the authors of
[33] proposed an alternative to the t-test for biomarker
discovery. In this approach, the idea was that a fraction of
the cancer samples would be positive for the biomarker(s)
of interest so that a t-test would fail to capture the differ-
ence. The mixture models described in this paper provide
model-based alternatives to the nonparametric testing
procedure proposed in [33]. A second interpretation of eij
pertains to the false discovery rate [9]. The false discovery
rate is roughly defined to be the expected number of false
discoveries divided by the number of rejected hypotheses,
where the gene-specific null hypothesis is that there is no
differential expression for the gene. It can be shown that
for the mixture models in this paper, P(eij = 0|X) repre-
sents the Bayesian false discovery rate [34].
Integration of Transformed Data: Analysis Tools
Let Xk be the study-wise transformed expression data for
the study k. After fitting one of the two types of models
described previously, the data we have are ,
where  is a probability matrix with entries
 as described earlier. For a common set of N
genes that are profiled in each of the studies of interest,
data integration is subsequently based on the rescaled val-
ues , and results in a combined data matrix of dimen-
sion . These are the estimated POE values
obtained from fitting one of the two algorithms to each of
the separate datasets.
Treating the  as the new "data," we can now apply
standard microarray methodologies to them. Note that
one major assumption made is that the studies being
combined show relatively little between-study heteroge-
neity. This is a crucial assumption in meta-analysis [1] and
is not any different for the approach we describe here. If
this assumption fails, then in effect we would be attempt-
ing to combine quantities representing fundamentally dif-
ferent things.
One goal in genomic data analyses is determining which
genes are differentially expressed. There are many availa-
ble methods for doing this, such as SAM [29], analysis
using q-values [4] or Empirical Bayes methods [35]. These
methods provide adjusted t-statistics for comparing two
groups. The adjustment is for the multiple comparisons
problem; we prefer approaches based on the false discov-
ery rate because they tend to be less conservative and can
provide investigators with calibrated lists of genes that
they can then attempt to validate. In the example dis-
cussed in the Results section, the group label is the tumor
type (localized/metastatic).
Another important goal of genomic data analysis is to
determine if there exists a gene expression profile that can
distinguish the two groups. This is referred to as classifica-
tion and is widely performed in gene expression studies.
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We use the compound covariate predictor [36] here; other
classification procedures could also be used. The com-
pound covariate predictor method works as follows:
(a) Fit a univariate logistic regression model using group
label as the response and gene expression as the predictor;
obtain the estimated regression coefficient.
(b) Define a risk index as the weighted average of gene
expression, where the weight is the estimated regression
coefficient from step (a).
We will assess the performance of the genes found using
classification accuracy. If we want to assess the perform-
ance of the classifier, we must deal with the issue of train-
ing and testing the model using the same data. An honest
estimate of the prediction error rate is obtained using
leave-one-out cross-validation. Define the risk index for
sample j by , where  is the POE
value for gene i in sample j, j = 1, ...,  and 
is the effect estimate for gene i in the combined dataset
without the sample j. The risk index for sample j is a
weighted linear combination of the expression profiles of
the top p genes, where the ranking of the genes is based on
their corresponding significance in the univariate logistic
model fit. As a result, large positive values of RI indicate
high risk of failure, whereas large negative values of RI
indicate low risk of failure. Classification of sample j to
the risk groups is then based on the jth leave-one-out risk
index. The classifier is (X*) = I{RIj > c}, with c being the
empirical quantiles of the RI's. The number of genes p in a
classifier is also treated as a parameter and optimized to
minimize the prediction error rates. Note that to maintain
unbiasedness of the procedure, we re-fit the univariate
logistic regressions for each dataset with a withheld sam-
ple and re-rank genes based on the corresponding results.
One other issue involves the use of POE values on training
versus testing sets. As described in the previous section, we
can obtain POE values either using or not using the class
labels. In training sets, we typically use the class labels. We
cannot use them in the test set as this will lead to overfit-
ting. However, it is still possible to get POE values without
using the phenotypic information for the test set.
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